Mr. Speaker, Quebec has a high-tech industrial policy that covers the innovative pharmaceutical industry. The Prime Minister has met with investors. During those meetings, he was informed that innovative pharmaceutical companies in Canada do not have the right to appeal to protect their patents, as companies in Europe and the United States do. This situation affects a number of companies in Quebec and Ontario.
When will Canada create a right to appeal, allowing innovative companies to stand up to their competition and make the most of their assets, so that they can continue to invest in research and development and preserve these high-tech jobs?